Slides
Page 1
0 Investor Presentation | Q2FY27 October 27, 2026
Page 2
1 Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will" , "aim" , "will likely result" , "would" , "believe" , "may" , "expect" , "will continue" , "anticipate" , "estimate" , "intend" , "plan" , "contemplate" , “seek to" , "future" , "objective" , "goal" , "likely" , "project" , "should" , "potential" , "will pursue" , and similar expressions of such expressions may constitute "forward-looking statements“ . These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially f rom those suggested by the forward- looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
Page 3
2 “Q2 delivered strong sequential growth, led by new DDC capacity. With our second cartridge line commercial, H2 will see new launches and a significant ramp-up in commercial volumes. Biologics momentum remained strong, with yet another US biotech onboarded during the quarter. With additional capacity and partnerships, we are well set for the next phase of growth. ” Neeraj Sharma CEO & MD New DDC capacity drives strong YoY revenue and EBITDA growth Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹95.17 1 Adjusted PAT excludes exceptional items (Q2FY27: ₹18m) and scheme related intangible amortisation (Q2FY27: ₹344m) ( Q2FY27 Performance Snapshot ) ₹5,162m $54.2m ₹1,633m $17.2m 32% ₹937m $9.8m 37% YoY Revenue EBITDA 329 bps YoY EBITDA margin Adjusted PAT1 53% YoY 109% YoY 32% QoQ 15% QoQ 416 bps QoQ 47% QoQ